10-Q: Inotiv Reports Q2 2026 Results Amidst Financial Strain

Inotiv, Inc. (NOTV) filed its Form 10-Q for the quarter ended March 31, 2026, revealing a significant increase in net loss and highlighting substantial going concern risks due to debt obligations and covenant compliance.

Summary

• Inotiv, Inc. reported a total revenue of $117.65 million for the three months ended March 31, 2026, a decrease of 5.4% compared to the same period in 2025.
• For the six months ended March 31, 2026, total revenue was $238.53 million, a decrease of 2.3% year-over-year.
• The company reported a consolidated net loss of $32.47 million for the three-month period, a substantial increase from the $14.87 million loss in Q2 2025.
• The net loss for the six-month period widened to $60.85 million from $42.50 million in the prior year.
• As of March 31, 2026, Inotiv had cash and cash equivalents of $15.18 million, down from $21.74 million at September 30, 2025.
• The company's financial statements are prepared under the assumption of a going concern, but substantial doubt exists due to negative operating cash flows, operating losses, and impending debt maturities.
• Inotiv is actively exploring strategic alternatives, including recapitalization, refinancing, or restructuring, to address its liquidity needs and debt obligations.
• The company received waivers for certain financial covenants under its Credit Agreement for the period ended March 31, 2026, but forecasts noncompliance for the remainder of fiscal 2026 without operational improvements or a liquidity-enhancing transaction.
• A critical risk is the potential for cross-default across its various debt instruments if any single default occurs, which could lead to acceleration of all outstanding debt.
• The company received a Nasdaq delisting notice due to failing to maintain a minimum bid price of $1.00 per share and has until June 29, 2026, to regain compliance.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the significant increase in net loss, declining revenues in key segments, severe liquidity concerns, impending debt maturities, and the explicit statement of substantial doubt about the company's ability to continue as a going concern, compounded by a Nasdaq delisting warning.

Positives

• Discovery and Safety Assessment (DSA) segment revenue increased by 3.9% to $47.08 million for the three months ended March 31, 2026, driven by higher safety assessment revenue.
• DSA segment operating income improved significantly to $1.01 million from an operating loss of $0.06 million in the prior year's comparable period.
• DSA segment revenue increased by 7.8% to $95.04 million for the six months ended March 31, 2026, with notable growth in Safety Assessment (SA) and Discovery and Translational Sciences (DTS) services.
• DSA segment operating income more than doubled to $4.16 million for the six months ended March 31, 2026, compared to $1.89 million in the prior year.
• The book-to-bill ratio for the DSA services business was 1.14x for the three months and 1.15x for the six months ended March 31, 2026, indicating strong future demand for DSA services.
• DSA backlog increased to $151.82 million at March 31, 2026, up from $138.20 million at September 30, 2025.

Negatives

• Total revenue decreased by 5.4% to $117.65 million in the three months ended March 31, 2026, primarily due to a 10.7% decline in Research Models and Services (RMS) revenue.
• Consolidated net loss widened significantly to $32.47 million for the three months ended March 31, 2026, from $14.87 million in the prior year.
• Consolidated net loss for the six months ended March 31, 2026, increased to $60.85 million from $42.50 million in the prior year.
• RMS segment revenue decreased by 10.7% to $70.57 million for the three months ended March 31, 2026, largely due to lower non-human primate (NHP) volumes sold.
• RMS segment reported an operating loss of $1.93 million for the three months ended March 31, 2026, a significant decline from an operating income of $11.43 million in the prior year.
• RMS segment operating loss widened to $5.48 million for the six months ended March 31, 2026, compared to an operating income of $10.25 million in the prior year.
• Unallocated corporate expenses increased by 28.4% to $18.18 million for the three months ended March 31, 2026, driven by cybersecurity incident costs and expenses related to exploring strategic alternatives.
• Cash and cash equivalents decreased to $15.18 million as of March 31, 2026, from $21.74 million at September 30, 2025.
• The company failed to make an interest payment of approximately $2.14 million on its Convertible Bond Indenture due April 15, 2026, with a grace period expiring May 15, 2026, which could trigger an event of default.
• The company received a Nasdaq delisting notice for failing to meet the minimum bid price rule and has a deadline to regain compliance.

Risks

• Substantial doubt exists about the Company's ability to continue as a going concern due to negative operating cash flows, operating losses, and impending debt maturities.
• The company forecasts noncompliance with financial covenants under its Credit Agreement for the remainder of fiscal 2026 without operational improvements or a liquidity-enhancing transaction.
• The Term Loan Facility, Delayed Draw Term Loan, Incremental Term Loans, revolving credit facility, and Second Lien Notes all mature within the next 12 months.
• Failure to comply with financial covenants could lead to an event of default under the Credit Agreement, potentially allowing lenders to accelerate all outstanding debt.
• Acceleration of loans under the Credit Agreement would constitute a default under the Convertible Senior Notes and Second Lien Notes, potentially leading to their acceleration as well.
• If all debt is accelerated, the company's existing cash and cash equivalents may not be sufficient to fund operations and satisfy all obligations.
• The company is exploring potential recapitalization, reorganization, refinancing, or restructuring transactions, but there is no assurance of successful completion on acceptable terms.
• The company received a Nasdaq delisting notice due to failing to maintain a minimum bid price of $1.00 per share, with a deadline to regain compliance by June 29, 2026.
• Dependence on NHP imports from outside the U.S. poses risks related to supply chain disruptions, price volatility, and potential import restrictions.
• The company's significant indebtedness may impair its ability to raise capital, pursue strategic investments, or service its debt obligations.
• The company is subject to ongoing legal proceedings, including securities class action and derivative lawsuits, privacy class actions, and an Envigo class action, although settlements have been reached for some.
• The company entered into a Resolution Agreement and Plea Agreement with the DOJ to resolve a criminal investigation into its former canine breeding facility, involving significant fines and compliance obligations.
• The company experienced a cybersecurity incident in August 2025, which may have led to the acquisition of certain data and is subject to ongoing litigation.

Future Outlook

Management's fiscal 2026 annual operating plan forecasts noncompliance with financial covenants. The company believes its current cash and cash equivalents, along with cash generated from operations, will not be sufficient to fund operations and satisfy obligations for the next 12 months without a transaction that positively impacts liquidity and reduces debt. The company is exploring strategic alternatives. The company received a Nasdaq delisting notice and is considering options, including a reverse stock split, to regain compliance.

Management Comments

• Management has developed our fiscal 2026 annual operating plan in which we plan to continue our efforts to optimize our capital allocation and expense base.
• The Company's plan is to continue its efforts to improve its operating results with a sustained focus on client service and margin discipline, increasing our volume of DTS and safety assessment contract awards and increasing our RMS product and service revenue.
• However, the Company believes its existing cash and cash equivalents, together with cash generated from operations, will not be sufficient to fund its operations and satisfy its obligations for the next 12 months, absent a transaction that positively impacts the Companys liquidity and reduces its debt obligations.
• Further, management's fiscal 2026 annual operating plan forecasts noncompliance with its financial covenants pursuant to the Credit Agreement.
• We intend to continue to monitor the bid price for our common shares and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Rule, including seeking shareholder approval of a reverse split of our common shares in order to increase the trading price of our common shares in compliance with the Minimum Bid Price Rule.

Industry Context

StockSavvy.ai notes that Inotiv's performance reflects broader trends in the contract research organization (CRO) sector, where companies are navigating increased demand for specialized services like safety assessment and drug discovery, while also facing economic pressures and regulatory scrutiny. The company's focus on expanding DSA services aligns with the industry's shift towards more complex, higher-value offerings, but the significant financial challenges and debt load present a considerable headwind.

Comparison to Industry Standards

• While specific comparable company data for Q2 2026 is not available in this filing, Inotiv's revenue decline in the RMS segment and widening net loss are concerning when compared to the general growth observed in the broader CRO market, which has seen increased R&D spending by pharmaceutical and biotech companies.
• The company's book-to-bill ratio of 1.14x for DSA services is positive and suggests demand for these services is outstripping current revenue recognition, a trend generally seen as healthy within the CRO industry.
• However, Inotiv's substantial debt load and ongoing covenant compliance issues are significantly more severe than typical industry benchmarks, placing it in a precarious financial position compared to well-capitalized peers like Charles River Laboratories or Labcorp, which generally maintain stronger balance sheets and consistent profitability.

Corporate Governance

Legal Proceedings

• Securities Class Action: Settled, with final approval granted January 27, 2026. Company paid $8.75 million, funded by insurance.
• Derivative Actions: Settled, with final approval granted March 19, 2026. Settlement involved corporate governance changes and a $2.25 million attorneys' fee award, funded by insurance.
• Privacy Class Actions: Federal actions dismissed March 14, 2026; similar action filed in Indiana State Court.
• Envigo Class Action (PAGA): Settlement preliminarily approved June 18, 2025, and in part on March 25, 2026. Awaiting amended final approval order. Settlement amount of $795,000 to be paid in four quarterly installments.
• Resolution Agreement and Plea Agreement: Company agreed to resolve a criminal investigation into its former canine breeding facility. Involves $22,000 in fines, compliance obligations, and a five-year monitorship.

Related Party Transactions

• Seller Note - Bolder BioPath: $38,000 outstanding as of March 31, 2026 (down from $150,000 at September 30, 2025).

Stakeholder Impact

• Shareholders: Potential for significant share price decline due to financial distress, going concern issues, and Nasdaq delisting risk. Dilution risk from potential capital raises.
• Creditors/Lenders: Increased risk of default and potential acceleration of debt due to covenant breaches and upcoming maturities. Waivers have been granted, but future compliance is uncertain.
• Employees: Uncertainty regarding the company's future operations and potential impact on job security. Management is focused on improving operating results and client service.
• Customers: Potential disruption to services if the company's financial situation deteriorates further. However, the DSA segment shows strong backlog, indicating continued demand for services.

Next Steps

• Regain compliance with Nasdaq's Minimum Bid Price Rule by June 29, 2026, or face potential delisting.
• Address the missed interest payment on Convertible Senior Notes by May 15, 2026, to avoid an event of default.
• Continue to discuss business conditions with lenders and explore strategic alternatives to improve liquidity and reduce debt.
• Implement operational improvements and cost-saving measures to improve financial performance and potentially comply with debt covenants.
• Complete Phase Two of the site optimization plan for the RMS business by the end of fiscal 2026.
• Monitor the impact of tariffs on NHP imports and pursue potential refunds of previously paid tariffs.

Key Dates

Recommendation

The company is facing severe financial distress, evidenced by widening net losses, declining revenues, significant going concern risks, impending debt maturities, and a Nasdaq delisting warning. The missed interest payment and potential for cross-defaults across its debt instruments create a high probability of a catastrophic financial event. While the DSA segment shows promise, it is overshadowed by the overwhelming financial and operational challenges. Investors should consider selling their holdings due to the substantial risk of capital loss.

Keywords

Inotiv, 10-Q, Quarterly Report, Contract Research Organization, CRO, Drug Discovery, Safety Assessment, Research Models, NHP, Financial Results, Net Loss, Liquidity, Going Concern, Debt, Credit Agreement, Covenants, Nasdaq, Delisting, Resolution Agreement, Plea Agreement, Cybersecurity Incident